HARTMANN USA wins exclusive U.S. distribution rights for SweetBio wound care product

HARTMANN USA is taking over exclusive nationwide commercial distribution of SweetBio’s VERIS advanced wound care product starting Nov. 1, 2026. The deal broadens access to a collagen and Mānuka honey treatment for acute and chronic wounds through HARTMANN’s national sales force.

Why it matters: - The agreement gives clinicians and patients broader access to a differentiated wound care option through HARTMANN USA’s national commercial network. - HARTMANN adds VERIS™, a product designed for acute and chronic wound management, to its advanced wound care portfolio. - The partnership combines SweetBio’s bioengineered technology with HARTMANN’s U.S. sales reach and clinical relationships.

What happened: - HARTMANN USA announced an exclusive national commercial distribution agreement with SweetBio®. - HARTMANN USA will become the exclusive nationwide commercial distribution partner for VERIS™, SweetBio’s advanced wound care product. - Distribution through HARTMANN USA will begin on Nov. 1, 2026. - The announcement was made in Rock Hill, South Carolina.

The details: - VERIS™ is intended for the management of acute and chronic wounds. - The product uses a patented formulation featuring collagen derivative and Mānuka honey. - SweetBio’s patented MX® technology combines collagen derivative, Mānuka honey and hydroxyapatite into a single bioengineered wound care solution. - HARTMANN says its established commercial infrastructure and national sales organization will expand access to VERIS™ across the United States. - Jon Procopio, managing director of HARTMANN USA, said VERIS™ complements the company’s existing advanced wound care portfolio and gives clinicians another option to support wound healing. - Kayla Rodriguez Graff, founder and CEO of SweetBio, said the partnership is designed to help bring innovative wound care technologies to more clinicians, care settings and patients.

Between the lines: - The deal signals HARTMANN’s push to deepen its position in advanced wound care with a product that emphasizes clinical differentiation. - For SweetBio, the agreement provides a national distribution channel that could expand commercial reach without building a larger direct sales operation. - The pairing of patented biomaterials and a large U.S. distributor suggests both companies are betting on clinician demand for simpler wound care options.

What's next: - HARTMANN USA will begin distributing VERIS™ nationally on Nov. 1, 2026. - Clinicians and care settings across the U.S. are expected to gain broader access once the distribution channel goes live. - The companies will likely use the partnership to expand awareness of SweetBio’s wound care products, including VERIS™ and APIS®, which SweetBio says are FDA-cleared and Medicare-covered.

The bottom line: - HARTMANN is expanding its wound care portfolio while giving SweetBio a national path to market through a single exclusive distribution agreement.